英国批准使用Mirikizumab, 首种用于克罗恩的IL-23瞄准药物, UK approves mirikizumab, first IL-23-targeting drug for Crohn’s, for NHS use.

新的克罗恩疾病治疗,即Mirikizumab(Omvoh),已在英国获得批准,不久将在国民保健制度上提供,30天内在英格兰开始,60天内在威尔士开始。 A new Crohn’s disease treatment, mirikizumab (Omvoh), has been approved in the UK and will soon be available on the NHS, with rollout starting in England within 30 days and Wales within 60 days. NICE和苏格兰医药联合会建议,这是第一种针对IL-23的药物,一种与炎症相关的蛋白质。 Recommended by NICE and the Scottish Medicines Consortium, it is the first drug to target IL-23, a protein linked to inflammation. 临床试验显示,25%的病人在12周内获得缓解,45%的病人在一年后获得缓解,而在安慰剂中则有20%的病人获得缓解,有些病人的肠道明显愈合。 Clinical trials showed 25% of patients achieved remission within 12 weeks and 45% after one year, compared to 20% on placebo, with visible bowel healing seen in some. 治疗是针对中度至重度克朗氏病的成年人,而这些人没有对其他生物药物有反应,治疗包括每四周一次的初始静脉注射,然后自行注射. The treatment, intended for adults with moderate to severe Crohn’s who haven’t responded to other biologics, involves initial IV infusions every four weeks followed by self-administered injections. 它带来各种风险,包括感染和副作用,如头痛和肝酶升高,并且是在专科护理下规定的。 It carries risks including infections and side effects like headaches and elevated liver enzymes, and is prescribed under specialist care.